Slingshot members are tracking this event:
MacroGenics (MGNX) to complete Phase 1b/2 combination study of Margetuximab and Pembrolizumab in patients with advanced, metastatic gastric cancer in late 2016
Do you think this event is important to the companies below? How will it affect their stock price?
Treatment options for patients with advanced HER2-positive gastric cancer are extremely limited. The combination of complementary mechanisms engaged by margetuximab and pembrolizumab could provide an important alternative for patients who do not respond to currently available regimens.
Slingshot Insights Explained
Dec 13, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Drug Combinations, Phase 1/2 Trial, Margetuximab, Pembrolizumab, Gastric Cancer